Skip to main content

Table 4 Comparison of clinical and demographic data in MTX non-responders vs responders (n = 1356)

From: Assessing the risk of rapid radiographic progression in Hungarian rheumatoid arthritis patients

Parameter MTX non-responders (n = 691) MTX responders (n = 665) p
Age (years) 52.99 ± 12.15 58.16 ± 13.98 < 0.001
Female gender (%) 84 86 0.365
Disease duration (years) 8.17 ± 8.73 8.72 ± 8.92 0.292
RF positivity (%) 76 75 0.442
RF absolute level (IU/ml) 153.55 ± 203.52 123.89 ± 187.21 0.002
ACPA positivity (%) 72 70 0.139
CRP level (mg/l) 21.24 ± 25.73 14.00 ± 21.01 < 0.001
DAS28 score 5.99 ± 0.68 3.98 ± 1.61 < 0.001
Swollen joint count (n) 8.87 ± 4.98 4.01 ± 4.74 < 0.001
Current MTX therapy (%) 83 45 < 0.001
MTX therapy ever (%) 96 89 < 0.001
current csDMARD therapy (other than MTX) (%) 44 25 < 0.001
csDMARD therapy ever (other than MTX) (%) 82 71 < 0.001
Presence of erosions (%) 67 61 0.033
Current smoker (%) 29 23 0.030
Risk of RRP (%) 37.82 ± 6.64 15.25 ± 8.90 < 0.001
Risk of RRP – if switched to (infliximab (%) 6.54 ± 4.18 5.84 ± 2.00 0.408